TY - JOUR
T1 - Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis
AU - Bjornevik, Kjetil
AU - O’Reilly, Éilis J.
AU - Berry, James D.
AU - Clish, Clary B.
AU - Jeanfavre, Sarah
AU - Kato, Ikuko
AU - Kolonel, Laurence N.
AU - Le Marchand, Loic
AU - McCullough, Marjorie L.
AU - Paganoni, Sabrina
AU - Schwarzschild, Michael A.
AU - Talbott, Evelyn O.
AU - Wallace, Robert B.
AU - Zhang, Zhongli
AU - Manson, Jo Ann E.
AU - Ascherio, Alberto
N1 - Publisher Copyright:
Copyright © 2018 American Academy of Neurology.
PY - 2019/4/30
Y1 - 2019/4/30
N2 - Objective To assess whether prediagnostic levels of plasma branched-chain amino acids (BCAAs) are associated with amyotrophic lateral sclerosis (ALS) risk. Methods We included participants from 5 large cohort studies—The Nurses’ Health Study, the Health Professionals Follow-up Study, the Cancer Prevention Study II Nutrition, the Multiethnic Cohort Study, and the Women’s Health Initiative—and identified 275 individuals who developed ALS during follow-up. Two controls were randomly selected for each case, matched on cohort, age, sex, fasting status, and time of blood draw. We measured metabolites using liquid chromatography–mass spectrometry and used conditional logistic regression to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for the association of individual BCAAs with ALS risk. Results None of the 3 BCAAs was associated with a higher ALS risk. The risk estimates were similar for leucine (RR top vs bottom quartile: 0.87, 95% CI 0.57–1.33), isoleucine (RR top vs bottom quartile: 0.81, 95% CI 0.52–1.24), and valine (RR top vs bottom quartile: 0.80, 95% CI 0.52–1.23) in a multivariable analysis adjusted for body mass index, smoking, level of education, and physical activity. The estimates did not vary significantly by sex, fasting status, or time interval between blood draw and disease onset. Conclusion The results from this study do not support the hypothesis that BCAAs are risk factors for ALS.
AB - Objective To assess whether prediagnostic levels of plasma branched-chain amino acids (BCAAs) are associated with amyotrophic lateral sclerosis (ALS) risk. Methods We included participants from 5 large cohort studies—The Nurses’ Health Study, the Health Professionals Follow-up Study, the Cancer Prevention Study II Nutrition, the Multiethnic Cohort Study, and the Women’s Health Initiative—and identified 275 individuals who developed ALS during follow-up. Two controls were randomly selected for each case, matched on cohort, age, sex, fasting status, and time of blood draw. We measured metabolites using liquid chromatography–mass spectrometry and used conditional logistic regression to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for the association of individual BCAAs with ALS risk. Results None of the 3 BCAAs was associated with a higher ALS risk. The risk estimates were similar for leucine (RR top vs bottom quartile: 0.87, 95% CI 0.57–1.33), isoleucine (RR top vs bottom quartile: 0.81, 95% CI 0.52–1.24), and valine (RR top vs bottom quartile: 0.80, 95% CI 0.52–1.23) in a multivariable analysis adjusted for body mass index, smoking, level of education, and physical activity. The estimates did not vary significantly by sex, fasting status, or time interval between blood draw and disease onset. Conclusion The results from this study do not support the hypothesis that BCAAs are risk factors for ALS.
UR - https://www.scopus.com/pages/publications/85065478461
U2 - 10.1212/WNL.0000000000006669
DO - 10.1212/WNL.0000000000006669
M3 - Article
C2 - 30429276
AN - SCOPUS:85065478461
SN - 0028-3878
VL - 92
SP - E2081-E2088
JO - Neurology
JF - Neurology
IS - 18
ER -
